The information set forth in the documents posted on this page was factually accurate on the date it was issued. While this information remains on Merck's Web site, the company assumes no duty to update the information to reflect subsequent developments. Consequently, readers of this information should not rely on it as current or accurate after the issuance dates.

29 July 2008	Merck to Seek Appellate Review of Class Certification Decision in VIOXX Proceedings in Ontario ( PDF* 23KB)
17 July 2008	Merck to Fund U.S. VIOXX® Product Liability Resolution Program
23 June 2008	Merck & Co. Asks to Appeal Court Ruling Certifying a Class of Missouri Plaintiffs Seeking Reimbursement for Out-of-pocket VIOXX® Costs ( PDF* 17KB)

• More

25 July 2007	Statement Regarding the Publications of Two VIOXX® Studies: The ViP Trial in Current Medical Research and Opinion and The VICTOR Trial in the New England Journal of Medicine ( PDF* 22KB)
03 July 2007	VIOXX® Update: Statement on VICTOR Study ( PDF* 22KB)
12 Sep 2006	Merck Statement about COX-2 Inhibitor Review Studies in the Journal of the American Medical Association ( PDF* 23KB)

• More

06 Sep 2006	Report of The Honorable John S. Martin, Jr. to the Special Committee of the Board of Directors of Merck & Co., Inc. Concerning the Conduct of Senior Management in the Development and Marketing of VIOXX®
06 Sep 2006	Statement on the Martin Report by William G. Bowen ( PDF* 8KB)
06 Sep 2006	Merck & Co., Inc. Statement on the Martin Report ( PDF* 16KB)

• More

* Some files are presented in PDF format. This software is available at no charge through the Adobe Web site. Get Adobe Reader